Specialty Drug Updates

Neurology Clinical Coverage

Specialty-focused drug approvals, safety updates, trial context, and clinical reference coverage for healthcare professionals.

Clinical Coverage

Search drug updates and clinical coverage.

8 loaded

CGRP inhibitors erenumab, fremanezumab, and galcanezumab reduce migraine frequency, offering new prevention options.

FDA approves Zycubo for Menkes disease: 78% reduction in mortality risk in pediatric patients.

FDA approves ofatumumab and natalizumab for multiple sclerosis: high-efficacy options for patients with relapsing forms.

FDA approves donanemab for Alzheimer: 27% cognitive decline reduction in mild AD patients.

CGRP inhibitors like erenumab and fremanezumab show significant efficacy in migraine prevention, reducing attack frequency effectively.

FDA approves Zycubo for Menkes disease: 78% survival benefit in pediatric patients.

Atogepant (Qulipta) approved for episodic migraine prevention: 50% reduction in monthly migraine days.

Ofatumumab and natalizumab show high efficacy in multiple sclerosis treatment: 50% and 68% reduction in relapse rates and disability progression.